WaveMan
WaveMan · Company
BIVI · Biovie Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BIVI Biovie (BIVI) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001580149
Quote by TradingView
Cluster · 4 insidersC-suite buying · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
16
13F, latest reported quarter

What the filings say about BIVI

Insiders, 180 days
+$49.1K net bought
4 buyers

Biovie insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, BIOVIE INC. insiders bought a net $49.1K of stock across 16 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
KIM JOANNE WENDY
Chief Financial Officer
BUY
2026-08-28 SEC
2,500
$5.5K
-36.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 7, 2021.
  • The trade is 72.7% of the 3,441 shares held after it.
  • 3 other insiders bought within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer KIM JOANNE WENDY bought about $5.5K of BIVI on Aug 28, 2026; 3 other insiders bought within 30 days and 16 funds added in the latest 13F quarter.
Chappell Amy Suzon
Director
BUY
2026-08-28 SEC
727
$1.6K
-36.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 727 shares held after it.
  • 3 other insiders bought within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Chappell Amy Suzon bought about $1.6K of BIVI on Aug 28, 2026; 3 other insiders bought within 30 days and 16 funds added in the latest 13F quarter.
Palumbo Joseph M
Chief Medical Officer
BUY
2026-08-28 SEC
4,843
$10.5K
-36.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 80.2% of the 6,036 shares held after it.
  • 3 other insiders bought within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Palumbo Joseph M bought about $10.5K of BIVI on Aug 28, 2026; 3 other insiders bought within 30 days and 16 funds added in the latest 13F quarter.
DO CUONG V
President & CEO
BUY
2026-08-28 SECtraded 2026-08-27
15,210
$31.6K
-36.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 30, 2023.
  • The trade is 94.4% of the 16,117 shares held after it.
  • 3 other insiders bought within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO DO CUONG V bought about $31.6K of BIVI on Aug 27, 2026, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 16 funds added in the latest 13F quarter.
DO CUONG V
President & CEO
BUY
2025-08-13 SECtraded 2025-08-07
5,000
-
-13.3%
16 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 11 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$49.1K over 180 days
+$49.1K over 90 days
more than 73% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
16 funds bought in last quarter
below 72% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
11.1% of the float short (float per yahoo 2026-10-26) · 2.7 days to cover · settled 2026-09-30
more than 75% of Pharma & Biotech
The situation: each line is one rule over one dataset
4 insiders independently bought a net $49.1K while the stock fell 16% over six months, with no planned sales queued.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BIVI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-23.8%12M
-49%-26%-3%+21%2025-102025-122026-022026-042026-062026-082026-10 2026-08-27 · DO CUONG V bought $31.6K2026-08-28 · Palumbo Joseph M bought $10.5K2026-08-28 · KIM JOANNE WENDY bought $5.5K2026-08-28 · Chappell Amy Suzon bought $1.6K2026-03-25 · DO CUONG V filed a 5%+ stake (5.03%)2026-03-25 · Do & Rickles Investments, LLC filed a 5%+ stake (5.02%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BIVI: institutional holders (13F)

13F holdings, latest reported quarter
MORGAN STANLEY
605,471 sh
$1.2M
Diametric Capital, LP
1,006,636 sh
$835.4K
Warberg Asset Management LLC
613,426 sh
$276.0K
RENAISSANCE TECHNOLOGIES LLC
127,918 sh
$248.2K
ARMISTICE CAPITAL, LLC
500,000 sh
$225.0K

Congress trades in BIVI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
DO CUONG V
Activist 13D · 2026-03-25
5.03%
Do & Rickles Investments, LLC
Activist 13D · 2026-03-25
5.02%

BIVI planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

BIVI mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$78.7K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$137.6K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$15.5K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$3.4K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$327 position · as of 2026-05-31
0.0%
Blackstone Alternative Multi-Strategy Fund
$19 position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 2
0 active
1
Phase 3
0 active
1
Multi-phase
0 active
What changed recently
NE3107 in Adults With Neurological Symptoms of Long COVID
2026-09-23 · Active Not Recruiting → Completed
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $49.1K bought by insiders over 180 days, 16 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BIVI financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.01x
long-term debt only, 2021-03-31 (63 months older than the period end); equity 2026-06-30
Cash flow to debt
-304.40x
TTM operating cash flow over long-term debt only, 2021-03-31 (63 months older than the period end)
Return on equity
-150.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-123.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-152.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.9M
market value at close 2026-10-27 on 2026-08-10 shares, plus long-term debt only, 2021-03-31 (63 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-062025-062024-062023-06
Operating income-$22.7M-$18.1M-$32.2M-$45.1M
Net income-$22.1M-$17.5M-$32.1M-$50.3M
EPS (diluted)-3.05-12.12-73.05-15.47
Operating cash flow-$19.0M-$19.0M-$27.9M-$40.3M
Cash$9.0M$17.5M$23.8M$19.5M
SEC XBRL, fiscal years, as known on 2026-10-28

BIVI Stock Sonar score 5/7 axes

Find similar shapesCompare

BIVI ranks highest on insider conviction (83rd percentile) and financial health (41st), and lowest on profitability (19th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
19
Inputs
  • Return on equity-150.8% · 23 pct, sector of 545
  • Return on assets-123.3% · 19 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-152.3% · 15 pct, sector of 576
Financial health
41
Inputs
  • Debt to equity0.01x · 78 pct, sector of 352
  • Cash flow to debt-304.40x · 4 pct, sector of 371
Insider conviction
83
Inputs
  • Net Form 4 buying (codes P and S), 180d$49K · 72 pct, sector of 428
  • Insider buyers, 180d4 · 94 pct, sector of 437
Institutional and government
28
Inputs
  • Funds adding, latest quarter16 · 28 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
36
Inputs
  • Short interest, % of float+11.1% · 36 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BIVI filings, in plain words

Are Biovie insiders buying or selling BIVI?

In the 180 days to 2026-10-28, Biovie insiders were net buyers, a net $49.1K across purchases and sales reported on Form 4, by 4 buyers.

Read the full summary

In the 180 days to 2026-10-28, Biovie insiders were net buyers of BIVI, a net $49.1K across purchases and sales reported on Form 4 by 4 buyers. 4 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. The latest 5% ownership filing is a 13D by DO CUONG V, filed 2026-03-25, for 5.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies